ACE-031 (1mg)

Description

Product: ACE-031 (1mg) Product Overview: ACE-031 is a recombinant fusion protein consisting of a modified form of the activin receptor type IIB (ActRIIB) extracellular domain linked to the Fc portion of human IgG1. This soluble receptor construct functions as a ligand trap, binding members of the TGF-beta superfamily including myostatin (GDF-8), activin A, and GDF-11 with high affinity, thereby preventing their interaction with endogenous cell-surface receptors. Research Profile: ACE-031 has been investigated extensively in preclinical research models for its ability to modulate signaling pathways that regulate skeletal muscle mass, bone density, and metabolic homeostasis. - Myostatin inhibition: Studied for its capacity to sequester myostatin and related ligands, attenuating negative regulation of muscle growth via the ActRIIB/Smad signaling axis. - Muscle hypertrophy models: Evaluated in laboratory settings for its effects on lean muscle mass accrual and fiber cross-sectional area through blockade of catabolic TGF-beta superfamily signaling. - Bone mineral density: Investigated for potential effects on osteoblast differentiation and bone formation through modulation of activin and GDF-11 pathways. - Metabolic regulation: Explored for its downstream effects on energy metabolism, including adipose tissue remodeling and insulin sensitivity. - Ligand selectivity profiling: Characterized for its binding affinity spectrum across multiple TGF-beta superfamily ligands (myostatin, activin A, activin B, GDF-11, BMP-9, BMP-10) using surface plasmon resonance and competition binding assays. - Smad signaling modulation: Examined for its effects on Smad2/3 phosphorylation dynamics and downstream transcriptional responses in skeletal muscle and bone cell lines. - Satellite cell activation: Investigated for its indirect effects on muscle stem cell proliferation and differentiation through derepression of myostatin-mediated quiescence signaling. Key Research Applications: ACE-031 has been utilized in diverse research models to study musculoskeletal biology and metabolic regulation. - Muscle wasting disease models: Applied in laboratory investigations examining the prevention of muscle atrophy through ligand sequestration strategies. - Skeletal biology studies: Used to evaluate effects on bone turnover markers and trabecular bone architecture. - Pharmacokinetic profiling: Assessed for its serum half-life, biodistribution, and dose-response relationships in preclinical models. - Comparative ligand trap research: Employed alongside other ActRIIB-Fc constructs and follistatin variants to benchmark ligand sequestration efficacy and selectivity. - Fibrosis pathway investigation: Studied for its capacity to attenuate TGF-beta-mediated fibrotic signaling in muscle and organ tissue models. Specifications: Peptide Content: 1mg per vial Appearance: Lyophilized powder Storage & Handling: Store in a cool, dry environment protected from light and moisture. Reconstitution and handling should be performed using standard laboratory procedures and appropriate laboratory controls. Compliance Notice: For research use only. Not for human or animal consumption. Not intended for therapeutic or diagnostic use.